BioScrip, Inc. (BIOS)
BIOS Price and Sentiment
BIOS Latest news
Option Care (BIOS) reported earnings 30 days ago. What's next for the stock?
Option Care Health (BIOS) can currently access all hemophilia factor treatments.
National leader in treating bleeding disorders offers personalized, high-quality patient care National leader in treating bleeding disorders offers personalized, high-quality patient care
Albeit Option Care Health (BIOS) is yet to reap material benefits from its merger-related synergies, the reporting of a positive gross margin in third-quarter results is encouraging for investors.
Option Care (BIOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioScrip (BIOS) is highly upbeat about the strategic and financial virtues of Option Care consolidation.
BioScrip (BIOS) delivered earnings and revenue surprises of 16.67% and 0.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
BioScrip, Inc. (BIOS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
BioScrip's stock extends plunge after merger terms disappoint, but analyst recommends remaining bullish2019-03-18 13:59
Shares of BioScrip Inc. tumbled 9.0% toward a 9-month low in midday trade Monday.
Shares of BioScrip Inc. soared 32% toward a 4-year high in premarket trade Friday.